Gene Techno Science Signs an Agreement with Kishi Kasei to Co-Develop Biosimilar of Aflibercept

 Gene Techno Science Signs an Agreement with Kishi Kasei to Co-Develop Biosimilar of Aflibercept

Gene Techno Science Signs an Agreement with Kishi Kasei to Co-Develop Biosimilar of Aflibercept

Shots:

  • GTS and Kishi Kasei will jointly develop biosimilar of Aflibercept and will form a manufacturing process for the drug substance utilizing high-yield protein-producing cell lines, which were jointly developed by GTS and Fuso Pharmaceutical
  • The collaboration focusses to secure a future revenue base via commercialization of biosimilar of Aflibercept and to gain market share in ophthalmologic diseases
  • The companies will partner with others to jointly promote drug development, non-clinical studies, clinical studies, manufacturing and approvals, sales, etc. and create a business structure for commercialization of the product

Click here to­ read full press release/ article | Ref: GTS | Image: Kabu Fx Trends

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post